What is Gerovital H3?
Gerovital H3 (Gerovital H3) is a local anesthetic. Gerovital H3 causes loss of feeling (numbness) of skin and mucous membranes.
Gerovital H3 is used as an injection during surgery and other medical and dental procedures.
Gerovital H3 may also be used for purposes other than those listed here.
Gerovital H3 indications
Injection
Percutaneous infiltration anaesthesia
Adult: 350-600 mg using 0.25 or 0.5% solutions.
Peripheral nerve block Adult: 500 mg Gerovital H3 HCl as a 0.5%, 1% or 2% solution. Up to 1 g may be used. Your healthcare provider will administer Gerovital H3 as an injection. Gerovital H3 is used for inducing local anaesthesia (loss of sensation) during surgical operations, dental procedures or other such medical procedures. A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Generic name: Gerovital H3 Dosage form: injection, USP The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist. As with all local anesthetics, the dose of Gerovital H3 varies and depends upon the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, individual tolerance, and the technique of anesthesia. The lowest dose needed to provide effective anesthesia should be administered. For specific techniques and procedures, refer to standard textbooks. 10% Solution (mg) (lumbar interspace) (mL) (mL) extremities The diluent may be sterile normal saline, sterile distilled water, spinal fluid; and for hyperbaric technique, sterile dextrose solution. The usual rate of injection is 1 mL per 5 seconds. Full anesthesia and fixation usually occur in 5 minutes. STERILIZATION The drug in intact ampuls is sterile. The preferred method of destroying bacteria on the exterior of ampuls before opening is heat sterilization (autoclaving). Immersion in antiseptic solution is not recommended. Autoclave at 15-pound pressure, at 121°C (250°F), for 15 minutes. The diluent dextrose may show some brown discoloration due to caramelization. Protect solutions from light. How should I use Gerovital H3?
Uses of Gerovital H3 in details
Gerovital H3 description
Gerovital H3 dosage
Gerovital H3 Dosage
Extent of Anesthesia Gerovital H3 Total Dose Site of Injection Volume of 10% Solution Volume of Dilution Perineum 0.5 0.5 50 4th Perineum and lower 1 1 100 3rd or 4th Up to costal margin 2 1 200 2nd, 3rd or 4th More about Gerovital H3 (Gerovital H3)
Professional resources
- Gerovital H3 (AHFS Monograph)
- Gerovital H3 (FDA)
Related treatment guides
- Local Anesthesia
Gerovital H3 interactions
See also:
What other drugs will affect Gerovital H3?
Anticholinesterases
Concurrent use of Gerovital H3 and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of Gerovital H3.
Antimyasthenics
Concurrent use of Gerovital H3 and antimyasthenics may result in loss of control of symptoms of myasthenia gravis due to antagonism of the effects of antimyasthenics on skeletal muscle. Temporary dosage adjustment of antimyasthenics may be required. Also antimyasthenics may have anticholinesterase activity.
CNS depressant medications
Concurrent use of Gerovital H3 and CNS depressant medications may result in additive depressant effects.
Hyaluronidase
Hyaluronidase may increase the diffusion rate of Gerovital H3, resulting in a decreased time of onset, but an increase in systemic toxicity.
Neuromuscular blocking agents (such as suxamethonium chloride)
Concurrent use of Gerovital H3 and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.
Sulfonamides
Concurrent use of Gerovital H3 and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.
Acetazolamide
Concurrent use of acetazolamide and Gerovital H3 may extend the plasma half-life of Gerovital H3.
Gerovital H3 side effects
See also:
What are the possible side effects of Gerovital H3?
Reactions to Gerovital H3 are characteristic of those associated with other ester-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels which may be due to overdosage, rapid absorption, inadvertent intravascular injection, or slow metabolic degradation.
A small number of reactions may result from hypersensitivity, idiosyncrasy, or diminished tolerance to normal dosage.
Systemic:
The most commonly encountered acute adverse experiences which demand immediate countermeasures are related to the central nervous system and the cardiovascular system. These adverse experiences are generally dose related and due to high plasma levels which may result from overdosage, rapid absorption from the injection site, diminished tolerance, or from unintentional intravascular injection of the local anesthetic solution. In addition to systemic dose-related toxicity, unintentional subarachnoid injection of drug during the intended performance of nerve blocks near the vertebral column (especially in the head and neck region), may result in underventilation or apnea (“Total or High Spinal”). Factors influencing plasma protein binding, such as acidosis, systemic diseases which alter protein production, or competition of other drugs for protein binding sites may diminish individual tolerance.
Plasma cholinesterase deficiency may also account for diminished tolerance to ester-type local anesthetics.
Central Nervous System Reactions:
These are characterized by excitation and/or depression. Restlessness, anxiety, dizziness, tinnitus, blurred vision, or tremors may occur, possibly proceeding to convulsions. However, excitement may be transient or absent, with depression being the first manifestation of an adverse reaction. This may quickly be followed by drowsiness merging into unconsciousness and respiratory arrest.
The incidence of convulsions associated with the use of local anesthetics varies with the procedure used and the total dose administered.
Cardiovascular Reactions:
High doses or inadvertent intravascular injection may lead to high plasma levels and related depression of the myocardium, decreased cardiac output, heartblock, hypotension (or sometimes hypertension), bradycardia, ventricular arrhythmias, and cardiac arrest.
Allergic:
Allergic-type reactions are rare and may occur as a result of sensitivity to the local anesthetic or to other formulation ingredients, such as the antimicrobial preservative chlorobutanol contained in multiple-dose vials. These reactions are characterized by signs such as urticaria, pruritus, erythema, angioneurotic edema (including laryngeal edema), tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and, possibly, anaphylactoid-like symptomatology (including severe hypotension). Cross sensitivity among members of the ester-type local anesthetic group has been reported. The usefulness of screening for sensitivity has not been definitely established.
Neurologic:
The incidences of adverse neurologic reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered, and are also dependent upon the particular drug used, the route of administration, and the physical status of the patient. Many of these effects may be related to local anesthetic techniques, with or without a contribution from the drug.
Gerovital H3 contraindications
See also:
What is the most important information I should know about Gerovital H3?
Spinal anesthesia with Gerovital H3 is contraindicated in patients with generalized septicemia: sepsis at the proposed injection site; certain diseases of the cerebrospinal system, e.g., meningitis, syphilis; and a known hypersensitivity to the drug, drugs of a similar chemical configuration, or aminobenzoic acid or its derivatives.
The decision as to whether or not spinal anesthesia should be used in an individual case should be made by the physician after weighing the advantages with the risks and possible complications.
Active ingredient matches for Gerovital H3:
Procaine in Romania.
Procaine hydrochloride in Hong Kong.
List of Gerovital H3 substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Gerovital H-3 | |
| Hewedolor Procain (Germany) | |
| Hewedolor-Procain (Germany) | |
| Hewedolor-Procain 2% (Germany) | |
| Injectio Polocaini hydrochlorici (Poland) | |
| Injectio Procaini Chlorati Ardeapharma (Czech Republic) | |
| Jenacain | |
| Jenacaine | |
| K.H.3-Geriatricum Schwarzhaupt (Austria) | |
| Lenident (Italy) | |
| Lenident Zeta (Italy) | |
| Lophakomp-Procain (Germany) | |
| Lophakomp-Procain N | |
| Mericaine | |
| Mericaine gel .04 g/g (Merit Pharmaceutical (US)) | |
| Minocain (Germany) | |
| Minocain 2% (Germany) | |
| Nissocaine | |
| Novacaine (Georgia) | |
| Novanaest (Austria) | |
| Novanaest purum 1% (Austria) | |
| Novanaest purum 2% (Austria) | |
| Novocain (Georgia, United States, Vietnam) | |
| Injectable; Injection; Procaine Hydrochloride 1% (Abbott) | |
| Injectable; Injection; Procaine Hydrochloride 2% (Abbott) | |
| 2 milliliter in 1 ampule (Abbott) | |
| 30 milliliter in 1 vial, multi-dose (Abbott) | |
| 6 milliliter in 1 ampule (Abbott) | |
| Novocain 3% Thephaco (Vietnam) | |
| Novocain 3% Thephaco 100 tube x 2 mL | |
| Novocain-Suprarenin (Germany) | |
| Novocaini Kalceks (Latvia) | |
| Novocainum (Georgia) | |
| Novokaino (Lithuania) | |
| Novokaino 0.25% Endokrininiai preparatai (Lithuania) | |
| Novokaino 0.5% Sanitas (Lithuania) | |
| Novokaino 1% Ilsanta (Lithuania) | |
| Novokaino EP (Lithuania) | |
| Novokaino Sanitas (Lithuania) | |
| Novokains (Latvia) | |
| Novokains 1% (Lithuania) | |
| Novokains 2% (Lithuania) | |
| Novokains Grindeks (Lithuania) | |
| Ntcain (Turkey) | |
| Omnicain (Japan) | |
See 187 substitutes for Gerovital H3 | |
References
- PubChem. "procaine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "procaine". http://www.drugbank.ca/drugs/DB00721 (accessed September 17, 2018).
- DTP/NCI. "procaine: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Gerovital H3 are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Gerovital H3. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet2 consumers reported age
| Users | % | ||
|---|---|---|---|
| > 60 | 2 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
